Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study (VON TRAPP)

11 maggio 2026 aggiornato da: Matthew Tunbridge, Central Adelaide Local Health Network Incorporated

Vaccination Response Modulation With a Targeted Rapamycin Protocol (VON TRAPP) Study

This study will investigate dialysis recipients' responses to important vaccines.

Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Respiratory viruses are a significant cause of morbidity and mortality in Australia. Respiratory syncytial virus (RSV) and Influenza are major contributors to yearly respiratory virus epidemics that particularly affect older persons and persons with end-stage kidney disease.

Vaccination is available for the prevention of both RSV and Influenza, but unfortunately the conditions that confer a higher risk of morbidity and mortality with infection are also key predictors of poor responses to vaccination.

Effective vaccine responses require activation of both T and B cells to generate protective and long-lasting antibody and cellular immune responses. Immunosenescence from ageing and end-stage kidney disease, dampens antibody responses and impairs cellular immunity, rendering patients vulnerable to infection.

Previous research suggests that sirolimus(rapamycin)-based immunosuppression regimens improve vaccine immunogenicity. Sirolimus (rapamycin) is a potent inhibitor of mTORC1 which regulates memory CD8+ T cells. Targeting mTORC1 has previous been shown to improve vaccination response in humans to influenza. More recently, small studies have suggested improved responses to COVID vaccination in kidney transplant recipients switched to sirolimus (rapamycin)-based regimens.

This study will investigate a role for sirolimus (rapamycin) as a peri-vaccination immune modulation therapy. The VON TRAPP study is a phase 2a randomised clinical trial that aims to define the optimal, practical and tolerable regimen of peri-vaccination sirolimus (rapamycin) administration to positively modify vaccine responses. Haemodialysis patients over 60 years old will receive both Influenza and RSV vaccines plus either no additional treatment or a peri-vaccination regimen of sirolimus (rapamycin) to determine the most effective regimen to test further.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Royal Adelaide Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • End-stage kidney disease requiring in-centre haemodialysis three times per week as kidney replacement therapy
  • Aged >60 years

Exclusion Criteria:

  • Aged <60 years
  • Alternative haemodialysis regimens (e.g. twice-weekly haemodialysis, second-daily home haemodialysis)
  • Recent infection (<6 months) with proven Influenza A, Influenza B, or RSV

  • Current use of immunosuppressive medications, including:

    • Oral steroid at a dose equivalent of 5 mg/day prednisolone or greater
    • Mycophenolate mofetil
    • Azathioprine
    • Calcineurin inhibitors
    • mTOR inhibitors

  • Recent use of intravenous immunosuppressive medications (<6 months), including:

    • T-cell depleting agents (e.g. anti-thymocyte globulin)
    • B-cell depleting agents (e.g. rituximab)
    • Cyclophosphamide

  • Has a history of problems with side-effects associated with sirolimus use including

    • Angioedema
    • Active/recent opportunistic infection
    • Current or prior interstitial lung disease, non-infectious pneumonitis, organising pneumonia, or pulmonary fibrosis
    • Clinically significant pleural effusion or pericardial effusion
    • Active non-healing wounds, chronic skin ulcers, or planned major surgery/procedures
    • Current malignancy or recent malignancy with high recurrence risk
    • Severe or uncontrolled hyperlipidaemia
    • History of rhabdomyolysis
    • Severe hepatic impairment

  • Ongoing use of strong CYP3A4/P-gp inhibitors or inducers including

    • Inhibitors: Ketoconazole, Voriconazole, Itraconazole, Telithromycin, Clarithromycin
    • Inducers: Rifampicin, Rifabutin
  • Unable or unwilling to provide informed consent to participate in the trial
  • Known allergy to or intolerance of sirolimus (rapamycin) or the contents of the influenza or RSV vaccine

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Control
Influenza and RSV vaccination without additional treatment
Biologico: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologico: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Sperimentale: Pre-vaccine sirolimus group
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks after completing sirolimus course.
Biologico: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologico: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Droga: Sirolimus (RAPAMUNE)
All treatment groups will receive 9 doses of 2mg sirolimus over a 3 week period, at varying times relative to vaccination.
Altri nomi:
  • Rapamicina
Sperimentale: Peri-vaccine sirolimus group
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 1 week after commencing sirolimus course.
Biologico: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologico: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Droga: Sirolimus (RAPAMUNE)
All treatment groups will receive 9 doses of 2mg sirolimus over a 3 week period, at varying times relative to vaccination.
Altri nomi:
  • Rapamicina
Sperimentale: Post-vaccine sirolimus group
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks prior to commencing sirolimus course.
Biologico: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologico: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Droga: Sirolimus (RAPAMUNE)
All treatment groups will receive 9 doses of 2mg sirolimus over a 3 week period, at varying times relative to vaccination.
Altri nomi:
  • Rapamicina

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Vaccine-specific functional T cell memory
Lasso di tempo: Six weeks post vaccination
The change in functional T cell memory from baseline to six weeks post vaccine dose, measured as IFN-γ spot-forming units (SFU) by ELISpot following 18-hour stimulation of PBMCs with RSV peptides.
Six weeks post vaccination

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cellular immune response to vaccination
Lasso di tempo: Six weeks post vaccination
RSV vaccine-specific cellular immunity, measured as 1) change in frequency of CD8+ RSV F protein-specific T cells from baseline to six weeks post vaccine dose, identified by flow cytometry as CD8+CD134+CD69+ following 24-hour stimulation with a protein-derived peptide array (AIM, Activation-Induced Marker assay); 2) Change in frequency of RSV F protein-specific polyfunctional T cells from baseline to six weeks post vaccine dose. Polyfunctional T cells are defined as CD4+ T cells that produce more than one of IFN-γ, IL-2 and TNF identified by flow cytometry intracellular cytokine staining following 24-hour stimulation with a protein-derived peptide array (ICS, Intracellular Cytokine Staining assay).
Six weeks post vaccination
Vaccine-specific humoral immune response
Lasso di tempo: Six week post vaccination
Measures of vaccine-specific humoral immunity, measured as 1) Anti-RSV F protein IgM, IgA and IgG antibody titres 6 weeks following the vaccine dose; 2) Change in haemagglutination inhibition (HAI) titre of influenza strains contained in the 2026 vaccine from baseline to six weeks post vaccination.
Six week post vaccination
Incidence of infection post-vaccination
Lasso di tempo: Twelve months post vaccination
Incidence of RSV or Influenza infection in the study cohort from 3 weeks post vaccination to 12-month follow-up
Twelve months post vaccination
Incidence of Sirolimus (Rapamycin) Treatment-Emergent Adverse Events [Safety and Tolerability]
Lasso di tempo: Six week post vaccination
Safety and tolerability of 3-week course of low-dose sirolimus (rapamycin), measured as frequency of adverse events (including serious adverse events)
Six week post vaccination
Incidence of Immunization Treatment-Emergent Adverse Events [Safety and Tolerability]
Lasso di tempo: Six weeks post vaccination
Safety and tolerability of vaccine regimen, assessed by 1. Frequency of adverse events following immunization (AEFI), including adverse events of special interest (AESI) such as recurrence of autoimmune disease
Six weeks post vaccination
Quality of life questionnaire
Lasso di tempo: Six weeks post-vaccination
Quality of life following 3-week course of low-dose sirolimus (rapamycin) and vaccination, measured with the EQ-5D-5L quality of life questionnaire. This questionnaire reports on 5 functional domains using an ordinal scale from 1 (worst) to 5 (best) to provide a combined health state score.
Six weeks post-vaccination
Circulating IL-1β analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-1β from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IFN-α2 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IFN-α2 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IFN-γ analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IFN-γ from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating TNF-α analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors TNF-α from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating MCP-1 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors MCP-1 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-6 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-6 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating CXCL8 (IL-8)
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor CXCL8 (IL-8) from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-10 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-10 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-12p70 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-12p70 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-17A analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-17A from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-18 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-18 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-23 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-23 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-33 analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-33 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating CRP analysis
Lasso di tempo: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors CRP from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Central Adelaide Local Health Network Incorporated

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 maggio 2026

Completamento primario (Stimato)

1 luglio 2026

Completamento dello studio (Stimato)

1 luglio 2026

Date di iscrizione allo studio

Primo inviato

6 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 maggio 2026

Primo Inserito (Effettivo)

14 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

14 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2025/HRE00483

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Anonymized patient-level data created for the study will be available in a persistent repository upon publication. Data will be uploaded to figshare.com.

Periodo di condivisione IPD

Anonymized IPD will be made available in a persistent repository from the date of publication of trial findings.

Criteri di accesso alla condivisione IPD

Anonymized IPD will be publicly accessible by download from the persistent repository.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Adulti più anziani

Prove cliniche su Influenza vaccine (Sequiris Fluad Quad)

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Congo

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi